Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health, Inc. announced that Irene BecklundChief Accounting OfficerPrincipal Accounting Officer
Becklund has served as Chief Accounting Officer since April 2025 and as Principal Accounting Officer since November 2021. The company entered into an advisory agreement with her, effective October 10, 2026, under which she will continue supporting the company in an advisory capacity through July 10, 2027.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported an option exercise and related share sale in Class A Common Stock. Okupe exercised stock options to acquire 7,163 shares at a price of $5.0100 per share, then sold 7,163 shares at an average price of $36.4863 per share.
These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025. Following the transactions, Okupe holds 284,321 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021, along with 102,361 stock options remaining outstanding.
Issuer: HIMS Holdings Corp. Reported Form 144 notices show multiple sales of Common stock by Oluyemi Okupe, executed on various dates in April–June 2026. Individual transactions range from 1,438 shares to 55,383 shares, with corresponding proceeds shown in the filing.
The filing indicates some shares were acquired as compensation via stock options and disposed via cashless exercise / same-day sale. Dates and per-transaction proceeds are listed for each sale in the excerpt.
Hims & Hers Health, Inc. entered into a Master Receivables Purchase Agreement allowing its subsidiaries XeCare LLC and Apostrophe Pharmacy LLC to sell eligible receivables to JPMorgan Chase Bank for cash, subject to a $400,000,000 facility limit. The arrangement has an initial 364‑day term and can be extended by mutual agreement. The company provided a Performance Undertaking guaranteeing the subsidiaries’ performance under the agreement, but not the collectability of receivables.
The company also executed Amendment No. 4 to its Revolving Credit and Guaranty Agreement to permit the receivables program, add a new permitted indebtedness basket up to $400,000,000 related to the facility, and align lien and collateral provisions. Other loan terms, including interest, fees, covenants and events of default, remain unchanged.
Hims & Hers Health, Inc. Chief Medical Officer Patrick Harrison reported an open-market sale of Class A Common Stock. He sold 23,726 shares at a price of $35.00 per share. After this transaction, he directly holds 181,861 shares of the company’s Class A Common Stock.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported an exercise of stock options and a sale of common shares. He exercised 6,376 shares of Class A common stock at $5.01 per share and sold 18,197 shares at an average price of $34.0285 per share. The filing states these option exercises and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025. Following the transactions, Okupe directly holds 284,321 shares of Class A common stock and indirectly holds 7,853 shares through the Oluyemi Okupe Separate Property Trust.
HIMS Holdings filed a Form 144 reporting proposed sales tied to restricted stock vesting of Class A shares. The notice lists 12,500 shares vesting on 03/15/2026 and 11,226 shares vesting on 06/15/2026.
The filing names Fidelity Brokerage Services LLC and references NYSE execution; transaction timing and proceeds treatment are not detailed in the excerpt.
Hims & Hers Health Chief Medical Officer Patrick Harrison reported routine equity compensation activity. On June 15, 2026, he acquired 25,926 shares of Class A Common Stock through the vesting and settlement of Restricted Stock Units (RSUs). To cover related tax withholding obligations, 8,310 shares were withheld by the company rather than sold on the open market.
Following these transactions, Harrison directly held 213,897 shares of Class A Common Stock. The RSUs vest under multi‑year, service-based schedules, with portions vesting on company quarterly vesting dates through future years.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported compensation-related equity activity involving Class A Common Stock and Restricted Stock Units (RSUs). On June 15, 2026, RSUs were exercised to deliver 71,616 shares of Class A Common Stock, reflecting vesting under prior equity awards. To cover associated tax withholding obligations, 39,541 shares of Class A Common Stock were withheld by the company at $30.17 per share, rather than sold on the open market. Following these transactions, Okupe directly held 296,142 shares of Class A Common Stock and indirectly held 7,853 shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The footnotes explain that each RSU converts into one share of Class A Common Stock and that the RSUs vest in substantially equal quarterly installments over four years, with first vesting dates ranging from June 15, 2023 to June 15, 2026.
Hims & Hers Health, Inc. Chief Policy Officer Deborah M. Autor reported routine equity compensation activity involving restricted stock units (RSUs). On June 15, 2026, 32,919 RSUs converted into an equal number of Class A Common shares. Of these, 15,396 shares were withheld at a price of $30.17 per share to cover tax obligations, leaving her with 48,961 Class A Common shares held directly after the transactions. Following the RSU conversion, she also held 460,873 RSUs, which carry a service-based vesting schedule over four years, vesting in substantially equal quarterly installments beginning on March 15, 2026.